The European market for antisera and related immunological products displays significant country-specific variations. In 2023, Ireland led the region with a sold production value of €22.004 billion, showcasing moderate growth at 5.75% year-on-year. France and Belgium emphasized their strong market positions with notable increases of 33.89% and 70.47%, respectively. Sweden and Germany also showed positive trends with moderate growth rates, while the United Kingdom experienced a decline of 11.23%. Eastern European countries like Poland saw a downturn. Over the past five years, the sector has witnessed fluctuating trends, suggesting variable market dynamics across regions.
Looking ahead to future trends, it is essential to monitor advancements in biotechnology and healthcare innovations, which are likely to impact production rates. Ireland's stable market and France and Belgium's rapid growth point towards potential leadership in manufacturing. Regulatory changes and investment in research could shift the landscape, making it crucial to follow policy updates and advancements in immunological research and production technology.
Top countries in Sold Production of Antisera, Other Immunological Products and Other Blood Fractions by Country
| # | 10 Countries | Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Ireland | 22,004,000,000 | 2023 | +5.93% | +5.75% | View data |
| 2 | 2 France | 5,452,700,000 | 2023 | +17.97% | +33.89% | View data |
| 3 | 3 Belgium | 3,952,100,000 | 2023 | +27.11% | +70.47% | View data |
| 4 | 4 Sweden | 2,278,900,000 | 2023 | +22.29% | +27.49% | View data |
| 5 | 5 Germany | 1,758,000,000 | 2023 | +1.51% | +3.02% | View data |
| 6 | 6 Austria | 662,510,000 | 2021 | +43.48% | View data | |
| 7 | 7 Spain | 389,740,000 | 2023 | -3.82% | +4.18% | View data |
| 8 | 8 United Kingdom | 373,160,000 | 2023 | -4.22% | -11.23% | View data |
| 9 | 9 Finland | 70,743,000 | 2023 | +10.05% | +3.4% | View data |
| 10 | 10 Denmark | 20,449,000 | 2023 | +7.82% | -14.22% | View data |
